WO2017049349A1 - Méthode de traitement et de prophylaxie - Google Patents

Méthode de traitement et de prophylaxie Download PDF

Info

Publication number
WO2017049349A1
WO2017049349A1 PCT/AU2016/050883 AU2016050883W WO2017049349A1 WO 2017049349 A1 WO2017049349 A1 WO 2017049349A1 AU 2016050883 W AU2016050883 W AU 2016050883W WO 2017049349 A1 WO2017049349 A1 WO 2017049349A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
level
signaling
pregnant
subject
Prior art date
Application number
PCT/AU2016/050883
Other languages
English (en)
Inventor
Evdokia DIMITRIADIS
Amy Louise WINSHIP
Original Assignee
Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903912A external-priority patent/AU2015903912A0/en
Application filed by Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research filed Critical Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research
Publication of WO2017049349A1 publication Critical patent/WO2017049349A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5431—IL-11
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le traitement ou la prévention de la pré-éclampsie ou de symptômes de celle-ci. La présente invention concerne également l'utilisation de biomarqueurs indiquant une pré-éclampsie ou un risque de développer une pré-éclampsie.
PCT/AU2016/050883 2015-09-25 2016-09-22 Méthode de traitement et de prophylaxie WO2017049349A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015903912A AU2015903912A0 (en) 2015-09-25 A method of treatment and prophylaxis
AU2015903912 2015-09-25

Publications (1)

Publication Number Publication Date
WO2017049349A1 true WO2017049349A1 (fr) 2017-03-30

Family

ID=58385468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2016/050883 WO2017049349A1 (fr) 2015-09-25 2016-09-22 Méthode de traitement et de prophylaxie

Country Status (1)

Country Link
WO (1) WO2017049349A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536921A (ja) * 2017-10-12 2020-12-17 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 平滑筋細胞媒介性疾患の治療

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099322A2 (fr) * 2002-05-24 2003-12-04 Isis Innovation Limited Derives d'il-11 et leurs utilisations therapeutiques
US20070178605A1 (en) * 2006-02-02 2007-08-02 Yale University Pregnancy biomarker profiles, methods and compositions related thereto
US20080233583A1 (en) * 2007-02-20 2008-09-25 Regents Of The University Of California Biomarkers for preeclampsia
US20140219919A1 (en) * 2013-02-07 2014-08-07 Csl Limited Il-11r binding proteins and uses thereof
WO2016083623A1 (fr) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Moyens pour le traitement de la prééclampsie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099322A2 (fr) * 2002-05-24 2003-12-04 Isis Innovation Limited Derives d'il-11 et leurs utilisations therapeutiques
US20070178605A1 (en) * 2006-02-02 2007-08-02 Yale University Pregnancy biomarker profiles, methods and compositions related thereto
US20080233583A1 (en) * 2007-02-20 2008-09-25 Regents Of The University Of California Biomarkers for preeclampsia
US20140219919A1 (en) * 2013-02-07 2014-08-07 Csl Limited Il-11r binding proteins and uses thereof
WO2016083623A1 (fr) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Moyens pour le traitement de la prééclampsie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUMASAWA K. ET AL.: "Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 108, 2011, pages 1451 - 1455, XP002701225 *
LOWNDES B. M. ET AL.: "Blair Bell abstracts: The effects of the anti-TNF therapy Certolizumab Pegol on extravillous trophoblast behaviour", BJOG: AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, vol. 119, 2012, pages e7 *
WINSHIP A. L. ET AL.: "Interleukin-11 alters placentation and causes preeclampsia features in mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 112, no. 52, 29 December 2015 (2015-12-29), pages 15928 - 15933, XP055370154 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536921A (ja) * 2017-10-12 2020-12-17 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 平滑筋細胞媒介性疾患の治療
US11780898B2 (en) 2017-10-12 2023-10-10 Singapore Health Services Pte Ltd. Treatment of SMC mediated disease

Similar Documents

Publication Publication Date Title
Winship et al. Interleukin-11 alters placentation and causes preeclampsia features in mice
Jones et al. Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases: potential interactions during decidualization and trophoblast invasion
Kim et al. Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis
JP4711972B2 (ja) 子癇前症又は子癇を鑑別するためのｉｎｖｉｔｒｏ分析方法
Salamonsen et al. Society for Reproductive Biology Founders’ Lecture 2009. Preparing fertile soil: the importance of endometrial receptivity
Bae et al. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome
KR20090040874A (ko) 임신 합병증의 진단 및 치료 방법
Plaisier et al. Different degrees of vascularization and their relationship to the expression of vascular endothelial growth factor, placental growth factor, angiopoietins, and their receptors in first-trimester decidual tissues
US7740849B2 (en) Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
Gutkowska et al. Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: effect of tumor necrosis factor blockade
US20090286271A1 (en) Methods of Diagnosing and Treating Complications of Pregnancy
Wu et al. CXCR2 is decreased in preeclamptic placentas and promotes human trophoblast invasion through the Akt signaling pathway
Waddell et al. CTGF expression is up-regulated by PROK1 in early pregnancy and influences HTR-8/Svneo cell adhesion and network formation
Denison et al. Prokineticin-1: a novel mediator of the inflammatory response in third-trimester human placenta
Löb et al. Interleukin-1 beta is significantly upregulated in the decidua of spontaneous and recurrent miscarriage placentas
Kishore et al. Prostaglandin dehydrogenase is a target for successful induction of cervical ripening
US20160333343A1 (en) Method of Treatment of Vascular Complications
Baryla et al. Prostaglandin F2α stimulates adhesion, migration, invasion and proliferation of the human trophoblast cell line HTR-8/SVneo
Paparini et al. Vasoactive intestinal peptide shapes first‐trimester placenta trophoblast, vascular, and immune cell cooperation
Berisha et al. Effect of the luteinising hormone surge on regulation of vascular endothelial growth factor and extracellular matrix-degrading proteinases and their inhibitors in bovine follicles
Chang et al. PLAC1 is involved in human trophoblast syncytialization
Winship et al. Fibulin-5 is upregulated in decidualized human endometrial stromal cells and promotes primary human extravillous trophoblast outgrowth
Zheng et al. Leukemia inhibitory factor promote trophoblast invasion via urokinase-type plasminogen activator receptor in preeclampsia
Marzioni et al. Activating protein-1 family of transcription factors in the human placenta complicated by preeclampsia with and without fetal growth restriction
Winship et al. Interleukin-11 up-regulates endoplasmic reticulum stress induced target, PDIA4 in human first trimester placenta and in vivo in mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16847647

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16847647

Country of ref document: EP

Kind code of ref document: A1